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the previous Korean liver allocation system was based on Child-turcotte-pugh scores, but increasing 
numbers of deceased donors created a pressing need to develop an equitable, objective allocation 
system based on model for end-stage liver disease scores (MeLD scores). A nationwide, multicenter, 
retrospective cohort study of candidates registered for liver transplantation from January 2009 to 
December 2011 was conducted at 11 transplant centers. Classification and regression tree (CART) 
analysis was used to stratify MELD score ranges according to waitlist survival. Of the 2702 patients that 
registered for liver transplantation, 2248 chronic liver disease patients were eligible. CART analysis 
indicated several MELD scores significantly predicted waitlist survival. The 90-day waitlist survival rates 
of patients with MELD scores of 31–40, 21–30, and ≤20 were 16.2%, 64.1%, and 95.9%, respectively 
(P < 0.001). Furthermore, the 14-day waitlist survival rates of severely ill patients (MELD 31–40, 
n = 240) with MELD scores of 31–37 (n = 140) and 38–40 (n = 100) were 64% and 43.4%, respectively 
(P = 0.001). Among patients with MELD > 20, presence of HCC did not affect waitlist survival 
(P = 0.405). Considering the lack of donor organs and geographic disparities in Korea, we proposed 
the use of a national broader sharing of liver for the sickest patients (MeLD ≥ 38) to reduce waitlist 
mortality. HCC patients with MELD ≤ 20 need additional MELD points to allow them equitable access to 
transplantation. Based on these results, the Korean Network for organ sharing implemented the MeLD 
allocation system in 2016.
Liver transplantation is the treatment of choice for end-stage liver disease, fulminant hepatic failure, and for 
selected cases of hepatocellular carcinoma (HCC), but the demand for liver grafts vastly exceeds supply world-
wide. In the West, efforts have focused on promoting deceased donor organ donation, and a model for end-stage 
liver disease score (MELD score) system has been implemented to enable equitable liver graft distribution1–4. On 
the other hand, in Asia the focus has been on living donor liver transplantation (LDLT)5, and the development of 
organ allocation system has been relatively neglected because deceased donation rates have been extremely low.
The previous Korean organ allocation system, which was introduced in 2000, was based on medical urgency 
and Child-Turcotte-Pugh scores (CTP scores). Although the shortcomings of the CTP score-based allocation 
system are well known6, they have not been of major concern in Korea due to the small number of deceased donor 
liver transplantation (DDLT) cases7. However, the number of deceased donors has increased since 2008, and there 
is now a growing need for an adequate, objective organ allocation system in Korea8.
The adoption of a MELD score-based system does not ensure equitable organ distribution9. In fact, MELD 
score-based systems have been continuously modified to enhance equity and efficiency4,10,11. Notably, the etiol-
ogies of liver diseases, medical environments, proportion of HCC, and donation rates are quite different in Asia 
and Western countries5. However, few studies have evaluated the feasibility of a MELD based allocation system 
in Korea7.
1Department of Surgery, Yonsei University college of Medicine, Seoul, Republic of Korea. 2the Advisory committee 
on improving Liver Allocation, Seoul, Republic of Korea. 3Department of Biostatistics and Medical informatics, Yonsei 
University college of Medicine, Seoul, Republic of Korea. *A comprehensive list of consortium members appears at 
the end of the paper. correspondence and requests for materials should be addressed to M.S.K. (email: ysms91@
yuhs.ac)
Received: 23 November 2018
Accepted: 1 May 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:7495  | https://doi.org/10.1038/s41598-019-43965-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
This study was undertaken to assess the feasibility of a MELD score-based allocation system using nationwide 
data. Based on this study, we sought to develop the Korean liver allocation system.
Results
Liver transplantation in Korea. The number of liver transplantations conducted annually in Korea 
reached a maximum of 1399 in 2015. LDLT accounts for the major proportion of liver transplantations conducted 
in Korea, and in 2015 the living donation rate was 18.73 per million population (PMP). However, numbers of 
LDLTs have remained static over the past few years despite the introduction of novel surgical techniques, whereas 
proportion of DDLT has increased steadily as a result of national efforts8. In 2015, DDLT accounted for 32.6% of 
liver transplantation cases (deceased donation rate 9.07 PMP, Fig. 1).
previous organ allocation system in Korea. In 2000, the Korean Network for Organ Sharing adopted 
the United Network for Organ Sharing classification for liver allocation, which is based on CTP score and status12. 
Highest priority (status 1) was given to patients with fulminant hepatic failure or acute graft failure within 7 days 
after liver transplantation. The next level of urgency was status 2A, which was defined as patients with chronic 
liver disease who had a CTP score of ≥10 and meet at least one of the other medical criteria (life-threatening 
variceal bleeding, refractory ascites/hydrothorax, hepatic encephalopathy, or hepatorenal syndrome), who were 
hospitalized in an intensive care unit with a life expectancy of <7 days without a liver transplant. Status 2B was 
defined as patients with chronic liver disease who had a CTP score of ≥10, or a CTP score of ≥7 and meet at least 
one of the medical criteria (life-threatening variceal bleeding, refractory ascites/hydrothorax, or spontaneous 
bacterial peritonitis). Patients with stage T1 and T2 HCC were allocated status 2B. Status 3 was established in 
patients who had a CTP score of ≥7 without meeting status 2B criteria.
Organ sharing areas in Korea consist of regional and national tiers since geographic distances are relatively 
short. The distribution policy based on arbitrary geographic boundaries divides Korea into three regions (Fig. 2). 
Region 1 includes the capital city (Seoul) and covers 30% of the land mass but accounts for 54% of the popula-
tion and 58% of transplant centers. This heterogeneity between regions is the result of regional organ donation 
and transplant activity differences. To reduce waiting list mortality for severely ill patients, regardless of region, 
the previous Korean allocation system offers national priority to Status 1 and 2A patients for 2 weeks from the 
registration.
Between 2011 and 2015, 57.2% of DDLTs (1088/1903) were performed in the urgent patients (8.1% in status 
1, 49.1% in status 2A). Status 2B patients were given the opportunity only if there were no status 1 or 2A patients 
on the waiting list13.
patient characteristics. A total of 2702 patients were placed on the liver transplantation waiting lists from 
January 2009 to December 2011 at the 11 transplantation centers. The exclusion criteria were pediatric candi-
dates, fulminant hepatic failure, and unknown liver disease. Baseline characteristics obtained at registration are 
provided in Table 1. Overall, mean age at registration was 53.5 years. The majority of 2248 patients were male 
(73.4%) and most (71.0%) were hepatitis B virus (HBV) carriers. Based on the CTP scoring system of liver func-
tions, 16.6% were class A, 41.7% were class B, and 41.7% were class C. Their mean laboratory MELD score was 
17.1, mean follow-up duration was 362 days, and 1071 (47.6%) had HCC. Compared to non-HCC patients, HCC 
patients were older (P < 0.001) and more likely to be male (P < 0.001). In addition, HCC patients were more likely 
to have HBV infection, but less likely to have alcoholic cirrhosis (P < 0.001). HCC patients tended to retain liver 
function at registration, and thus, had lower CTP and MELD scores than non-HCC patients (P < 0.001). Of the 
1395 status 2B patients, 122 non-HCC patients (18.3%) had a MELD score of >30, whereas only 14 HCC patients 
(1.9%) had a MELD score of >30.
Figure 1. Liver transplantations in Korea.
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MELD score distribution according to status are shown in Table 2. In the CTP score-based system, there was 
a broad range of liver disease severity in the same status. In addition, some status 2B candidates with high MELD 
score received lower priority than status 2A candidates with lower MELD score. In our cohort, 68 status 2A 
patients (42.8%) had a MELD score of ≤30, whereas 136 status 2B patients (10.0%) had a MELD score of >30.
Survival analysis for stratification. Using classification and regression tree (CART) analysis, we succes-
sively partitioned chronic liver disease patients into subgroups (Fig. 3A). CART analysis indicated that a MELD 
score cut-off of 20 was a primary determinant of waitlist survival. In patients with a MELD score of >20, the next 
most important cut-off score was 30. Ninety-day waitlist survival rates were 16.2% and 64.1% for patients with 
MELD scores 31–40 or 21–30, respectively. Patients with a MELD score of ≤20 had a 90-day waitlist survival rate 
of 95.9% (Fig. 3B).
severely ill patients (MeLD score >30). Of the 2248 study subjects, 240 (10.7%) had a MELD score of 
>30. However, short-term waitlist survival for these patients was not homogeneous, and thus, these 240 patients 
were partitioned into two subgroups by CART analysis. Patients with MELD score of <38 had a significantly 
lower waitlist removal rate than those with a MELD score of 38–40. For patients with MELD scores of 31–37 or 
38–40, 14-day waitlist survival rates were 64% and 43.4%, respectively (P = 0.001, Fig. 3C).
MeLD exception for hepatocellular carcinoma. In patients with a MELD score of >20, the presence 
of HCC did not affect waitlist survival (Fig. 4A). HCC patients with a MELD score of ≤20 were compared to 
non-HCC patients with certain MELD ranges. The MELD score ranges of non-HCC patients were chosen using 
CART analysis. The 90-day outcomes were similar for patients with HCC and a MELD score of <14 and patients 
without HCC and a MELD score of 14–17 (Fig. 4B), and waitlist survival rates were similar for patients with HCC 
and a MELD score of 14–20 and patients without HCC and a MELD score of 21–25 (Fig. 4C).
Discussion
The goal of organ allocation is to distribute organs in a fair and ethical fashion based on medical judgment. 
Because the number of DDLT procedures is increasing in Korea, there is a pressing need to reorganize the liver 
allocation system. Hence, we conducted this multicenter study to assess the feasibility of MELD score and to 
develop Korean liver allocation system based on MELD score.
The previous liver allocation system used in Korea prioritizes waitlist candidates based on medical urgency 
and CTP score, but although the CTP scoring system can be used to stratify disease severity intuitively, its dis-
criminatory ability is limited6,7. Hence, non-medical factors, such as, waiting time and center incentive have 
become the primary means of prioritizing patients within each status designation7,14. Furthermore, some status 
2B candidates with high MELD score received lower priority than status 2A candidates with lower MELD score. 
If liver grafts are allocated according to the MELD score, it is expected to reduce waiting list mortality.
The MELD score is a scoring system for assessing the severity of chronic liver disease and provide a con-
tinuous, transparent, and objective measure of 90-day waitlist mortality15,16. Hence, offering donor livers in 
Figure 2. Number of deceased donors and liver transplantation in Korea by geographic regions.
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descending MELD score order can be a simple and reliable means of liver allocation for chronic liver disease 
candidates. However, in the real world, geographic boundaries and supply-demand ratios should also be consid-
ered. Although not intended, MELD score-based allocation systems caused significant geographic disparities17. 
In addition, chronic liver disease patients with high MELD score had similar or even higher waiting list mortality 
than fulminant hepatic failure patients (status 1) who benefit from broader sharing of livers18. To address this 
issue, several countries implemented broader sharing of livers not only for the fulminant hepatic failure patients 
but also for the high MELD patients4,10,11,19. For such systems, arbitrary cut-off scores are chosen based on waitlist 
mortalities on a countrywide basis.
In the present study, CART analysis was used to identify arbitrary MELD score ranges that reflect meaningful 
waitlist survival differences in Korea. According to CART analysis, 90-day waitlist survival rates were found to be 
significantly different for MELD score ranges of 31–40, 21–30, and ≤20. Subgroup analysis showed the 14-day 
waitlist survival rate was 43.4% for patients with a MELD score of 38–40 and 64% for those with a MELD score of 
31–37. Accordingly, we proposed national broader sharing of liver allografts for the patients with MELD score of 
38 or higher in order to reduce waitlist deaths (Table 3).
MELD score does not allow fair access to liver transplantation for HCC patients because in these patients’ 
liver function is often preserved. For this reason, in many countries, selected HCC patients are awarded an arbi-
trary MELD score in an attempt to estimate the risk of HCC progression beyond Milan criteria3,4,16. However, 
the risk of waitlist removal due to HCC progression was much less than originally estimated. Despite constant 
adjustments, recent studies have demonstrated HCC patients have easier access to transplantation than non-HCC 
patients20–22. Furthermore, in Korea where LDLTs are performed in HCC patients beyond Milan criteria, equita-
ble selection is more complicated than in other countries. Hence, we compared waitlist survival rather than HCC 
progression to select HCC candidates warranting additional MELD points.
Prioritization within HCC candidates is another important issue. If all HCC candidates with a MELD 
score of ≤20 were awarded the same exceptional points, non-medical parameters would dominate allocations. 




HCC (n = 1177)
Patients with 
HCC (n = 1071) P-value
Age at listing (years) 53.5 ± 9.1 51.7 ± 9.6 55.5 ± 7.9 <0.001
Male, n (%) 1650 (73.4%) 823 (69.9%) 827 (77.2%) <0.001
Blood type, n (%) 0.971
    A 776 (34.5%) 403 (34.2%) 373 (34.9%)
    B 654 (29.1%) 344 (29.2%) 310 (28.9%)
    AB 250 (11.1%) 134 (11.4%) 116 (10.8%)
    O 568 (25.3%) 296 (25.2%) 272 (25.4%)
Body mass index (kg/m2) 24.1 ± 3.5 24.0 ± 3.7 24.2 ± 3.3 0.12
Original liver disease, n (%) <0.001
    Hepatitis B virus 1595 (71.0%) 707 (60.1%) 888 (82.9%)
    Hepatitis C virus 200 (8.9%) 93 (7.9%) 107 (10.0%)
    Alcoholic 360 (16.0%) 304 (25.8%) 56 (5.2%)
    Cholestatic 40 (1.8%) 37 (3.1%) 3 (0.3%)
    Others 53 (2.3%) 36 (3.1%) 17 (1.6%)
CTP class, n (%) <0.001
    A 374 (16.6%) 79 (6.7%) 295 (27.5%)
    B 938 (41.7%) 397 (33.7%) 541 (50.6%)
    C 936 (41.7%) 701 (59.6%) 235 (21.9%)
MELD score 17.1 ± 8.9 20.5 ± 9.2 13.4 ± 6.6 <0.001
Status*, n (%) <0.001
    2A 159 (7.1%) 122 (10.4%) 37 (3.5%)
    2B 1395 (62.1%) 665 (56.5%) 730 (68.2%)
    3 694 (30.8%) 390 (33.1%) 304 (28.3%)
Table 1. Patient characteristics. *Status based on previous Korean liver allocation system.
Status 2A (n = 159) Status 2B (n = 1395)
MELD ≤ 20 22 (13.8%) 968 (69.4%)
MELD 21–30 46 (28.9%) 291 (20.9%)
MELD 31–37 47 (29.6%) 85 (6.1%)
MELD 38–40 44 (27.7%) 51 (3.7%)
Table 2. MELD score distribution in status 2A and status 2B patients.
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distributions between HCC and non-HCC patients22–25. However, these models have not been well validated. 
Moreover, the use of tumor aggressiveness to determine priorities among HCC patients is likely to increase the 
risk of posttransplant HCC recurrence. On the other hand, laboratory MELD scores are known well predict HCC 
patient dropout from waitlists26. Hence, we developed an evidence-based model according to the waitlist survival 
rates of HCC and non-HCC patients in Korea. HCC MELD exception was determined through advisory meet-
ings based on our nationwide data27. The KONOS provides additional points for patients with T2 HCC based on 
laboratory MELD score (HCC patients with MELD score of <14 receive an additional 4 points and those with 
MELD score between 14 and 20 receive an additional 5 points). With the introduction of the MELD system in the 
current organ donation rate, we expect that HCC patients with preserved liver function are less likely to receive 
DDLT. In order to resolve the disparity in access to DDLT, efforts should be made not only to improve the alloca-
tion system but also to increase the number of deceased donors.
In the setting of organ scarcity, not only urgency but also utility or transplant outcome should be considered. 
In fact, reports issued in several countries have described poor post-transplant outcomes after adoption of a 
Figure 3. Waiting list survival. (A) Classification and regression tree; (B) Waiting list survival rate by MELD 
score; (C) Waiting list survival rate for severely ill patients.
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MELD system28. However, relation between MELD scores and survival following transplantation remains contro-
versial29,30. In addition, the high proportion of LDLTs conducted in Korea makes it much more difficult to predict 
the consequences of adopting a MELD system. Therefore, future studies are needed to assess the impact of MELD 
system on transplant outcomes.
The Korean liver allocation system is not perfect and there is room for improvement. First, we have not yet set 
exceptional points for other indications other than HCC. Instead, if a candidate’s transplant physician believes that a 
candidate’s MELD score does not appropriately reflect the candidate’s medical urgency, the physician may request an 
exceptional priority to the KONOS. Second, we do not have specific regulation for patients using vitamin K-antagonists. 
The international normalized ratio, which has the largest weight in the MELD score, is significantly affected by vitamin 
K-antagonists. The Eurotransplant has a specific regulation for patients using vitamin K-antagonists considering its 
importance3. Continuous efforts to improve allocation system will be needed in the future.
Despite its retrospective design and short follow-up, this is the first study to investigate the availability of 
the MELD score-based allocation system using national cohort data in Asia. Although MELD scores may accu-
rately predict waitlist mortality, they do not ensure equitable organ distribution9. Medical environments, organ 
Figure 4. Waiting list survival rates between HCC and non-HCC patients by MELD score. (A) Waiting list 
survival in HCC patients with MELD score of >20; (B) Waiting list survival in HCC patients with MELD score 
of <14; (C) Waiting list survival in HCC patients with MELD score of 14–20.
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donation rates, proportion of LDLT, and regional distributions differ markedly between countries. Hence, thor-
ough verification is required before adopting a new allocation system. We believe the present study may provide 
valuable basis for developing MELD score-based allocation system in other countries.
In conclusion, the MELD score system adequately stratified the short-term mortality rates of chronic liver 
disease patients on Korean waitlists. Regarding donor organ shortages and geographic disparities, we proposed 
the broader sharing of livers for the sickest patients (MELD score of ≥38) to reduce waitlist mortality. Our find-
ings demonstrated that HCC patients with a MELD score of ≤20 need additional MELD points to allow them 
equitable access to transplantation. The MELD score allocation system was finally implemented in Korea in 2016 
after a series of advisory committee meetings based on the results of this study.
Materials and Methods
subjects. A nationwide, multicenter, retrospective cohort study was performed on 2702 candidates registered 
for liver transplantation from January 2009 to December 2011 at 11 liver transplantation centers, which con-
ducted 83.1% of Korean liver transplantations (1047/1260) in 2012. The exclusion criteria applied were pediatric 
cases, fulminant hepatic failure, and unknown liver disease. Patients were followed until 31 March 2013 to ensure 
that all were followed for at least one-year. These patients were divided into two groups according to the presence 
of HCC (Fig. 5). All donor surgeries were performed with the consent of the donor and approval from the Korean 
Network Organ Sharing. No allografts (organs and tissue) obtained from prisoners were used.
parameters. Baseline information, such as, age, sex, body mass index, original liver disease, CTP score, pres-
ence of HCC, and blood type were obtained at time of registration.
MELD scores were calculated at the time of registration using the following equation:
MELD score (0 957 log creatinine 0 378 log bilirubin
1 12 log international normalized ratio 0 643) 10
e e
e
= . + .
+ . + . ∗ .
For this calculation, laboratory values of <1.0 were set at 1.0. The upper limit of serum creatinine was set at 
4.0 mg/dL, and MELD scores were capped at 40. For patients who received two or more dialysis within the last 
week, or 24 hours of continuous veno-venous hemodialysis, the creatinine value were set to 4.0 mg/dL.
outcomes. The primary outcome was waitlist survival. Candidates removed from the waitlist because of clin-
ical deterioration were considered to be equivalent to candidates that succumbed to chronic liver disease because 
clinical deterioration in such a situation is almost uniformly fatal without transplantation. These definitions are 
consistent with those used in previous studies18. For severely ill patients, we compared 14-day waitlist survival.
Waiting time was defined as time elapsed between registration and date of removal from the waiting list. 
Patients were censored if they were alive at last follow-up and on a waiting list or had been removed due to 
improvement or transplantation.
statistical analysis. Demographic information was summarized using frequencies (percentages) or 
means ± standard deviations. The Chi-square test with Fisher’s exact test was used to compare categorical vari-
ables and the student’s t-test was used to compare continuous variables. Survival and freedom from events were 
estimated using the Kaplan-Meier method and compared using the log-rank test.
CART analysis is a tree-based classification and prediction method that utilizes recursive partitioning to 
split records into segments with similar output field values. At each split, two child nodes are generated using a 
selected best predictor, at the next split, each child node may become a parent node and generate two child nodes. 
A unified framework was applied for recursive partitioning to avoid overfitting and variable selection problems31.
We performed CART analysis to identify MELD scores where the 90-day waitlist survival varies greatly. In 
severely ill patients, we compared waitlist survival within 14-day of listing18. Waitlist survivals were analyzed 
with respect to MELD scores and the presence of HCC in order to identify HCC candidates requiring additional 
MELD points. MELD score ranges were identified by CART analysis. Survival curves were compared using the 
log-rank test to identify MELD score adjustments for HCC patients that equalized waitlist outcomes for HCC and 
non-HCC patients.
US Liver allocation scheme (UNOS) Korean Liver allocation model (KONOS)
Combined local and regional status 1A/1B Combined regional and national status 1
Local/regional MELD score 35–40 (offers made 
locally then regionally for each MELD score)
Regional/national MELD score 38–40 (offers made 
regionally then nationally for each MELD score)
Local MELD score 15–34 Regional MELD score 31–37
Regional MELD score 15–34 National MELD score 31–37
National status 1A/1B Regional MELD score 21–30
National MELD score ≥15 National MELD score 21–30
Local MELD score <15 Regional MELD score ≤20
Regional MELD score <15 National MELD score ≤20
National MELD score <15
Table 3. Staged broader sharing model based on MELD score.
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The statistical analysis was performed using R (version 3.1.1; The R Foundation for Statistical Computing, 
Vienna, Austria), and P-values va0.05 were considered statistically significant.
ethical approval. All liver transplants were performed after obtaining informed consent at the 11 partici-
pating centers. The study was conducted according to the tenets of the Declaration of Helsinki and was approved 
by the Institutional Review Boards of Severance Hospital (2012-1142-001). Signed patient informed consent was 
waived per the IRB approval, since the study was a retrospective analysis.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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